DRI Healthcare Trust Acquires Royalty Interest in KalVista's Seb способов лечения Hereditary Angioedema Drug
核心洞察
DRI Healthcare Trust has acquired a royalty interest in sebetralstat, an oral on-demand therapy for hereditary angioedema (搜索) (HAE), from KalVista Pharmaceuticals.
The agreement includes an upfront payment of US$100 million, potential milestone payments up to US$57 million, and a US$5 million equity investment in KalVista.
Seb способов лечения Hereditary Angioedema (搜索) is under regulatory review by the FDA and EMA, with a PDUFA date set for June 17, 2025.
DRI Healthcare Trust has announced the acquisition of a royalty interest in sebetralstat, an investigational oral therapy developed by KalVista Pharmaceuticals for the on-demand treatment of hereditary angioedema (搜索) (HAE). The deal, valued at up to US$184 million, includes a US$100 million upfront payment, up to US$57 million in sales-based milestone payments, and a US$5 million investment in KalVista's common stock.
Seb способов лечения Hereditary Angioedema: A Promising Oral Treatment for HAE
HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts. Seb способов лечения Hereditary Angioedema (搜索), a novel oral plasma kallikrein (搜索) inhibitor, has demonstrated significant efficacy and a favorable safety profile in clinical trials, offering a potential alternative to existing injectable treatments. The FDA has accepted KalVista's New Drug Application (NDA) for sebetralstat, with a Prescription Drug User Fee Act (PDUFA) date of June 17, 2025. The European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for sebetralstat.
The Phase III KONFIDENT trial, a randomized, double-blind, placebo-controlled study, enrolled 136 adult and adolescent HAE patients. Results showed sebetralstat significantly reduced the time to symptom relief, attack severity, and complete attack resolution compared to placebo. The safety profile was similar to that of placebo.
Financial Terms and Royalty Structure
Under the agreement, DRI Healthcare Trust will receive a tiered royalty on net sales of sebetralstat: 5.00% on sales up to US$500 million, 1.10% on sales between US$500 million and US$750 million, and 0.25% on sales above US$750 million. KalVista is also eligible for a one-time sales-based milestone payment of US$50 million if annual worldwide net sales exceed US$550 million before January 1, 2031. An optional US$22 million payment to KalVista, if exercised, would increase the royalty rate on sales up to US$500 million to 6.00% and the milestone payment to US$57 million.
Strategic Implications for DRI Healthcare Trust
This acquisition marks DRI Healthcare Trust's first pre-approval royalty acquisition and equity investment, highlighting its evolving investment strategy. Ali Hedayat, Acting CEO of the Trust's investment manager, noted that sebetralstat's robust clinical data and potential long duration of cash flows make it an attractive asset. Navin Jacob, Chief Investment Officer, expressed confidence in sebetralstat's potential to become a foundational treatment for HAE.
KalVista intends to use the proceeds from the transaction to fund the continued clinical development and commercialization of sebetralstat. The royalty receipts for DRI Healthcare Trust are anticipated to continue through at least 2041.